

DMD #47274

Title page

Metabolism of Triethylenetetramine (TETA) and 1,12-diamino-3,6,9-triazadodecane (SpmTrien) by the Spermidine/spermine-N¹-acetyltransferase and Thialysine Acetyltransferase

Mervi T. Hyvönen, Janne Weisell, Alex R. Khomutov, Leena Alhonen, Jouko Vepsäläinen, Tuomo A. Keinänen

Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute (M.T.H., L.A.), School of Pharmacy (J.V., J.W., T.A.K.), Biocenter Kuopio, University of Eastern Finland, Kuopio Campus, P.O. Box 1627, FI-70211 Finland. Engelhardt Institute of Molecular Biology (A.K.), Russian Academy of Sciences, Vavilov Street 32, 119991 Moscow, Russia.

DMD #47274

Running tile page

Running title: Metabolism of TETA and SpmTrien by SSAT1 and SSAT2

Address correspondence to: Tuomo A. Keinänen, School of Pharmacy, Biocenter Kuopio, University of Eastern Finland, Kuopio Campus, Yliopistonranta 1 E (for courier), P.O. Box 1627, FI-70211 Finland.

E-mail: Tuomo.Keinanen@uef.fi

Number of text pages 15

Number of tables 0

Number of figures 3

References 15

Number of words in the abstract 164

Number of the words in the introduction 305

Number of the words Results and Discussion 817

Abbreviations

APAO, acetylpolyamine oxidase; DENSp_m, N¹,N¹¹-diethylnorspermine; FBS, fetal bovine serum; MAT, N¹-AcTETA; Put, putrescine; Spd, spermidine; Spm, spermine; SpmTrien, 1,12-diamino-3,6,9-triazadodecane; SSAT1, spermidine/spermine-N¹-acetyltransferase; SSAT2, thialysine acetyltransferase; TETA, triethylenetetramine (Trientine, Syprine[®])

DMD #47274

ABSTRACT:

Triethylenetetramine (TETA), a drug for Wilson's disease, is a copper chelator and a charge-deficient analog of polyamine spermidine. We recently showed that TETA is metabolized *in vitro* by polyamine catabolic enzyme spermidine/spermine-N¹-acetyltransferase (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT). The acetylation of TETA is increased in SSAT1-overexpressing mice as compared to wild-type mice. However, SSAT1-deficient mice metabolize TETA at the same rate as the wild-type mice, indicating the existence of another N-acetylase responsible for its metabolism in mice. Here, we show that siRNA-mediated knockdown of SSAT2 in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of TETA to MAT. By contrast, 1,12-diamino-3,6,9-triazadodecane (SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2, and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes. Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of TETA, whereas SpmTrien is primarily acetylated by SSAT1.

DMD #47274

INTRODUCTION

Triethylenetetramine (TETA, Trientine, Supplemental Fig. 1) is an alternative drug for Wilson's disease if the patient becomes intolerant to the primary medication with penicillamine (Walshe, 1969). TETA is a very efficient copper chelator, and very well tolerated. However, it is rapidly metabolized to its mono- (MAT) and diacetylated (DAT) derivatives (Lu et al., 2007). Recently, TETA has also shown potency in the treatment of other diseases such as diabetes-associated end-organ damage (Cooper, 2011), cancer (Yin et al., 2003) and Alzheimer's disease (Cooper, 2011).

TETA resembles the biogenic polyamine spermidine (Spd) in structure (Supplemental Fig. 1), but possesses only about + 2 net charge at the physiological pH as compared with + 3 that of Spd (Bencini et al., 1999; Frassinetti et al., 2003). The polyamines, Spd and spermine (Spm) are present at high concentrations in almost all cell types and are considered as mediators of important cellular functions such as proliferation, differentiation and tissue integrity (Pegg, 2009). We recently found that spermidine/spermine N¹-acetyltransferase (SSAT1), the key enzyme of polyamine catabolism, acetylates TETA *in vitro* and *in vivo* (Weisell et al., 2010; Cerrada-Gimenez et al., 2011). However, SSAT1-deficient (SSAT1-KO) mice metabolized TETA at the same rate as the wild-type mice did, indicating the presence of other enzyme(s) mainly responsible for its metabolism. Based on a databank/literature search, we found a structurally similar enzyme, thialysine acetyltransferase (SSAT2), which is encoded by a different gene than SSAT1 and metabolizes thialysine instead of polyamines (Coleman et al., 2004). Further assays with human recombinant enzyme showed that SSAT2 acetylated TETA at the same velocity as thialysine *in vitro* (Cerrada-Gimenez et al., 2011).

DMD #47274

We report here that SSAT2 is the primary enzyme metabolizing TETA in mouse primary hepatocytes and in human HEPG2 cells, whereas the charge-deficient Spm analog, 1,12-diamino-3,6,9-triazadodecane (SpmTrien, Supplemental Fig. 1) (Khomutov et al., 2007) is metabolized by SSAT1.

DMD #47274

MATERIALS AND METHODS

Hepatocyte isolation and culture

Hepatocytes were isolated from SSAT1-KO (Niiranen et al., 2006) and wild-type mice by collagenase digestion (detailed protocol in Supplemental data). The cells were transfected with control or SSAT2 siRNA (100 nM; Sigma-Aldrich) using siPORT NeoFX (Ambion).

Lentiviral-mediated RNA interference in HEPG2 cells

The cells were cultured in DMEM containing 15 % fetal bovine serum (FBS) and 50 µg/ml gentamycin at + 37 °C 5 % CO₂. The cells were transduced with control, SSAT1 or SSAT2 shRNA lentiviral particles (0.25x10⁶ IFU/6-well plate, Santa Cruz Biotechnology) and stable clones selected using puromycin hydrochloride (5 µg/ml, Sigma-Aldrich) for one week. The cells were plated onto 6-well plates and incubated overnight before treatments.

Recombinant protein assays

SpmTrien (100-5000 µM) was incubated with 10-100 ng of human recombinant SSAT1 or SSAT2 for 10 min at + 37 °C and analyzed as described previously (Weisell et al., 2010; Cerrada-Gimenez et al., 2011). The end products were also analyzed by HPLC (Hyvönen et al., 1992) (Detailed protocol in Supplemental data).

Analytical methods

Polyamines and SSAT1 activity were measured from cell lysates according to published methods (Libby, 1978; Hyvönen et al., 1992) (Detailed protocols in Supplemental data). The amount of DNA was measured using the PicoGreen reagent (Invitrogen). RNA was extracted using TRI

DMD #47274

Reagent (Sigma Aldrich), Dnase-treated (DNA-free, Ambion) and reverse transcribed (High Capacity cDNA synthesis kit, Applied Biosystems). SSAT1, SSAT2 and 18S rRNA expression levels were measured from cDNA using DynaZyme PCR kit (Finnzymes). For statistical analysis, one-way ANOVA with Tuckey's post-hoc test was used with the aid of GraphPad Prism 5.03 (GraphPad Software Inc.).

DMD #47274

RESULTS AND DISCUSSION

Metabolism of SpmTrien by human recombinant SSAT2

Previously determined kinetic values for TETA with human recombinant SSAT2 are K_m of 2.5 ± 0.3 mM and V_{max} of 3.96 ± 0.15 $\mu\text{mol}/\text{min}/\text{mg}$, and with human SSAT1 K_m of 83 ± 7 μM and a V_{max} of 0.90 ± 0.02 $\mu\text{mol}/\text{min}/\text{mg}$ (Cerrada-Gimenez et al., 2011). For SpmTrien, the kinetic values with mouse SSAT1 are K_m of 106 ± 6 μM and V_{max} of 1.17 ± 0.02 $\mu\text{mol}/\text{min}/\text{mg}$ (Weisell et al., 2010). Here we tested SpmTrien as a substrate for human recombinant SSAT2 by using P81 disk method (Libby, 1978). It was a very poor substrate, as the incorporation of C^{14} -label to N-AcSpmTrien was <0.4 pmol/10 min/ng (vs. TETA to MAT 15 pmol/10 min/ng) when using 5 mM substrate concentration and 100 ng of the enzyme. As analyzed by the HPLC method (Hyvönen et al., 1992), the incubation of SpmTrien with SSAT1 yielded 12.8 nmol of N^1 -AcSpmTrien and 4.2 nmol of N^{12} -AcSpmTrien when using 100 ng of enzyme with 1 mM SpmTrien for 50 min. Under the same conditions SSAT2 produced both N^1 - and N^{12} -AcSpmTrien in trace quantities, yielding 0.65 nmol of N^1 -AcSpmTrien and 1.1 nmol of N^{12} -AcSpmTrien. Thus, SSAT1 readily metabolized SpmTrien, preferring acetylation of the N^1 -end (aminoethyl) of the molecule.

Metabolism of TETA and SpmTrien in mouse primary hepatocytes

We next investigated the metabolism of TETA and SpmTrien in primary hepatocytes isolated from SSAT1-KO (devoid of SSAT1 activity) or wild-type mice. The cells were treated with control or SSAT2 siRNA for 3d, yielding knockdown efficiency of ~50% in both genotypes (Fig 1A). As indicated in Fig. 1C, SSAT2 siRNA-treated cells showed reduced (~50%) metabolism of TETA (1 mM) to MAT as compared to control siRNA-treated cells, and the reduction correlated

DMD #47274

with the knockdown efficiency, suggesting that SSAT2 is the main enzyme metabolizing TETA. By contrast, no metabolism of SpmTrien (100 μ M) was detectable in SSAT1-KO cells. In wild-type cells, SSAT2 knockdown did not reduce the metabolism of SpmTrien (100 μ M) to N¹-AcSpmTrien (Fig. 1D). In fact it led to the induction of SSAT1 activity (Fig. 1B) and increased metabolism of SpmTrien to N¹-AcSpmTrien (Fig. 1C).

Metabolism of TETA and SpmTrien in HEPG2 cells

The metabolism of TETA and SpmTrien was then investigated in human HEPG2 cells with functional SSAT1. Interestingly, HEPG2 cells showed apparently very low acetylpolyamine oxidase (APAO) activity, since large amounts of N¹-AcSpd and especially N¹-AcSpm, which is rarely detectable in cell samples, were found at the basal state (Supplemental Table 1). TETA was metabolized to MAT, and SpmTrien to N¹-AcSpmTrien, TETA and MAT, but at slower rate than in mouse primary hepatocytes. The metabolizing rates for TETA were 10 pmol MAT/h per μ g DNA in HEPG2 cells vs. 40 pmol MAT/h per μ g DNA in primary hepatocytes, and for SpmTrien 0.8 pmol N¹-AcSpmTrien/h per μ g DNA in HEPG2 cells vs. 3.4 pmol N¹-AcSpmTrien /h per μ g DNA in primary hepatocytes. When SSAT1 activity was induced by 24-h pretreatment with 50 μ M N¹,N¹¹-diethylnorspermine (DENSpm; a N¹N¹¹-diethylated Spm analog which induces SSAT1 activity at all levels of gene expression (Pegg, 2008)) before the addition of TETA or SpmTrien, the amounts of intracellular MAT and N¹-AcSpmTrien, respectively, were increased (Fig 2), indicating that SSAT1 could metabolize both TETA and SpmTrien. In addition, SpmTrien's other metabolite, N¹²-AcSpmTrien, became detectable in DENSpm-pretreated cells (data not shown).

DMD #47274

Next, the expression of SSAT1 or SSAT2 was knocked down in HEPG2 cells using stable lentiviral shRNA, which reduced SSAT1 and SSAT2 mRNA ~90% and ~35%, respectively, as compared to control siRNA (Fig. 3A). Like in primary hepatocytes, SSAT2 knockdown induced SSAT1 mRNA (Fig. 3A) and SSAT1 activity (Fig. 3B), but SSAT1 knockdown did not significantly affect SSAT2 mRNA level. SSAT1 knockdown led to a dramatic reduction of N¹-AcSpd and N¹-AcSpm pools, while SSAT2 knockdown did not affect acetylpolyamine levels (Fig. 3C). As indicated in Fig 3D, the metabolism of TETA to MAT was reduced with SSAT2 but not with SSAT1 shRNA. As expected, the metabolism of SpmTrien to N¹-AcSpmTrien was reduced with SSAT1 but not with SSAT2 shRNA (Fig. 3D).

Taken together, these data demonstrate that SSAT2 is the primary metabolizing enzyme for TETA, while SSAT1 is responsible for the metabolism of SpmTrien. However, SSAT1 can also contribute to the metabolism of TETA when it is induced at relatively high level, which occurs under various conditions such as inflammation and oxidative stress (Pegg, 2008). The cell culture data are in agreement with our previous findings where SSAT1-deficient mice metabolized TETA at the same rate as wild-type mice did, but SSAT1 overexpressing mice displayed increased acetylation (Cerrada-Gimenez et al., 2011). The higher cellular accumulation of SpmTrien and its metabolism to TETA may offer means to improve achieving the effective therapeutic level *in vivo* by using SpmTrien as a bioactive precursor of TETA. The suggested metabolic pathways of SpmTrien and TETA based on our current knowledge are summarized in (Supplemental Figure 2).

DMD #47274

Acknowledgments

The authors thank Ms. M. Heikkinen, Ms. A. Karppinen, Ms. A. Korhonen, Ms. T. Reponen and Ms. M. Salminkoski for their technical assistance, Dr. Myung Hee Park (NIH, USA) for human recombinant SSAT1 and SSAT2, and Prof. Jari Koistinaho (UEF, Finland) for HEPG2 cells.

Authorship contribution

Participated in research design: Hyvönen and Keinänen.

Conducted experiments: Hyvönen

Contributed to new reagents or analytic tool: Alhonen, Khomutov, Weisell, and Vepsäläinen.

Performed data analysis: Hyvönen and Keinänen.

Wrote or contributed to the writing of manuscript: Hyvönen, Alhonen, Khomutov, Weisell, Vepsäläinen and Keinänen.

DMD #47274

REFERENCES

- Bencini A, Bianchi A, Garcia-Espana E, Micheloni M, and Ramirez JA (1999) Proton coordination by polyamine compounds in aqueous solution. *Coordination Chemistry Reviews* **188**:97-156.
- Cerrada-Gimenez M, Weisell J, Hyvönen MT, Park MH, Alhonen L, Vepsäläinen J, and Keinänen TA (2011) Complex N-acetylation of Triethylenetetramine. *Drug metabolism and disposition: the biological fate of chemicals* **39**:2242-2249.
- Coleman CS, Stanley BA, Jones AD, and Pegg AE (2004) Spermidine/spermine-N¹-acetyltransferase-2 (SSAT2) acetylates thialysine and is not involved in polyamine metabolism. *Biochem J* **384**:139-148.
- Cooper GJ (2011) Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. *Drugs* **71**:1281-1320.
- Frassinetti C, Alderighi L, Gans P, Sabatini A, Vacca A, and Ghelli S (2003) Determination of protonation constants of some fluorinated polyamines by means of ¹³C NMR data processed by the new computer program HypNMR2000. Protonation sequence in polyamines. *Analytical and bioanalytical chemistry* **376**:1041-1052.
- Hyvönen T, Keinänen TA, Khomutov AR, Khomutov RM, and Eloranta TO (1992) Monitoring of the uptake and metabolism of aminoxy analogues of polyamines in cultured cells by high-performance liquid chromatography. *J Chromatogr* **574**:17-21.
- Khomutov AR, Grigorenko NA, and Skuridin SG (2007) Novel approach to design an isosteric charge-deficient analogue of spermine and its biochemically important derivatives. *Biochem Soc Trans* **35**:369-373.

DMD #47274

Libby PR (1978) Calf liver nuclear N-acetyltransferases. Purification and properties of two enzymes with both spermidine acetyltransferase and histone acetyltransferase activities.

The Journal of biological chemistry **253**:233-237.

Lu J, Chan YK, Gamble GD, Poppitt SD, Othman AA, and Cooper GJ (2007)

Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients. *Drug metabolism and disposition: the biological fate of chemicals* **35**:221-227.

Niiranen K, Keinänen TA, Pirinen E, Heikkinen S, Tusa M, Fatrai S, Suppola S, Pietilä M,

Uimari A, Laakso M, Alhonen L, and Jänne J (2006) Mice with targeted disruption of spermidine/spermine N1-acetyltransferase gene maintain nearly normal tissue polyamine homeostasis but show signs of insulin resistance upon aging. *J Cell Mol Med* **10**:933-945.

Pegg AE (2008) Spermidine/spermine-N(1)-acetyltransferase: a key metabolic regulator. *Am J*

Physiol Endocrinol Metab **294**:E995-1010.

Pegg AE (2009) Mammalian polyamine metabolism and function. *IUBMB life* **61**:880-894.

Walshe JM (1969) Management of penicillamine nephropathy in Wilson's disease: a new

chelating agent. *Lancet* **2**:1401-1402.

Weisell J, Hyvönen MT, Häkkinen MR, Grigorenko NA, Pietilä M, Lampinen A, Kochetkov SN,

Alhonen L, Vepsäläinen J, Keinänen TA, and Khomutov AR (2010) Synthesis and biological characterization of novel charge-deficient spermine analogues. *J Med Chem* **53**:5738-5748.

Yin F, Liu J, and Peng X (2003) Triethylene tetraamine: a novel telomerase inhibitor. *Bioorganic*

& medicinal chemistry letters **13**:3923-3926.

DMD #47274

Footnotes

[†]The research was supported by grants from the Academy of Finland; the Orion-Farmos Research Foundation; the Paulo Foundation; the strategic funding from the University of Eastern Finland; the Program of Molecular and Cell Biology of the Presidium of Russian Academy of Sciences; and the Russian Foundation for Basic Research [grant #12-04-92609].

[‡]The authors declare no competing financial interest

Leena Alhonen, Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, Biocenter Kuopio, University of Eastern Finland

Janne Weisell, Jouko Vepsäläinen, School of Pharmacy, Biocenter Kuopio, University of Eastern Finland

Alex Khomutov, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov Street 32, 119991 Moscow, Russia

Mervi T. Hyvönen, Department of Cell and Molecular Biology (CMB), Karolinska Institutet, P.O. Box 285, SE-17177 Stockholm, Sweden.

Tuomo A. Keinänen, Department of Microbiology, Tumor and Cell Biology (MTC), Nobels vägen 16, KI Solna Campus, Karolinska Institutet, Box 280, SE-171 77 Stockholm, Sweden

DMD #47274

Figure legends

FIG. 1. SSAT2 knockdown in primary hepatocytes from wild-type and SSAT1-KO mice A) SSAT2 mRNA level. B) SSAT1 activity. Amounts of intracellular C) MAT and D) N¹-AcSpmTrien after 4 h incubation with 1 mM TETA or 100 μM SpmTrien, respectively. SSAT2 mRNA was knocked down by 3-d siRNA treatment. Data are means ± SD, n=3.

FIG. 2. Effect of SSAT1 induction on the metabolism of A) TETA and B) SpmTrien in HEPG2 cells. The cells were pretreated with 50 μM DENSpm or medium only for 24 h. Then, the plates were washed and cells incubated with 1 mM TETA or 100 μM SpmTrien for 24 h, and samples analyzed for metabolites. Data are means ± SD, n=3.

FIG.3. SSAT1 or SSAT2 knockdown in HEPG2 cells. A) SSAT1 and SSAT2 mRNA levels. B) SSAT1 activity. C) Amounts of intracellular N¹-AcSpd and N¹-AcSpm. D) Amounts of MAT and N¹-AcSpmTrien after 24 h of incubation with 1 mM TETA or 100 μM SpmTrien, respectively. SSAT1 and SSAT2 mRNA were knocked down with stable lentiviral shRNA. Data are means ± SD, n=3.





A**B****C****D**

Figure 1




Figure 2

